QualityStocks

[QualityStocks]

QualityStocksNewsBreaks – InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Files Provisional Patent Covering Proprietary Biosynthesis Program

Preclinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) this morning announced its filing of a provisional patent application pertaining to the company’s biosynthesis program for the manufacture of cannabinoids that are identical to those found in nature. Per the news release, this patent application, once converted into an international Patent Cooperation Treaty (PCT) application and pursued in key jurisdictions around the world, will offer significant commercial protections for InMed’s promising E. coli-based expression system, which enables the manufacture of any of the 90+ cannabinoid compounds found in the cannabis plant. “This novel approach to the biosynthesis of cannabinoids is a game-changer for drug development,” Dr. Vikramaditya Yadav, Assistant Professor of Chemical and Biological Engineering at the University of British Columbia, stated in the news release. “The importance of producing cannabinoids that are identical to the naturally occurring compounds cannot be overstated. Many drug development efforts with synthetic derivatives have failed.”

To view the full press release, visit http://dtn.fm/ru1ZD

About InMed

InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed’s proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com.